Figure 3 | Scientific Reports

Figure 3

From: Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer

Figure 3

Treatment outcome according to dNLR value in the D group. (A) PFS and (B) OS in patients with dNLR ≤ 3 or > 3. (C) PFS and (D) OS in patients with dNLR28 ≤ 3 or > 3. dNLR, derived neutrophil-to-lymphocyte ratio; D group, durvalumab group; PFS, progression-free survival; OS, overall survival; NA, not applicable.

Back to article page